Author: Admin

Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference

From Startup Kezar Life Sciences Link to Full Article: http://investors.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-present-bmo-prescriptions-success-healthcare SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) — Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief

Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-present-bmo-capital-markets-2018-prescriptions-success EVANSTON, Ill., Dec. 05, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will participate in a fireside chat

Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

From Startup Anika Therapeutics Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-resumes-global-distribution-hyalofast-hyalograft-c-and Company Expands HYALOFAST Commercial Reach in Asia, the Middle East and Latin America BEDFORD, Mass.–(BUSINESS WIRE)–Dec. 4, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”)

Kallyope Inc. Announces $21 Million Expansion of Series B Financing

From Startup Kallyope Link to Full Article: https://www.kallyope.com/kallyope-inc-announces-21-million-expansion-series-b-financing/ December 5th, 2018 Entry of Bill Gates and additional investment from existing syndicate raises Series B total to $87 million Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $21 million expansion of

BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2379449 Poster highlights enrichment strategies for clinical trials in ALS NEW YORK, Dec. 04, 2018 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that

Lexington, Mass. – December 3, 2018

From Startup Kaleido Link to Full Article: https://kaleido.com/kaleido-biosciences-announces-appointment-of-katharine-knobil-m-d-as-chief-medical-officer-and-head-of-research-development/ Lexington, Mass. – December 3, 2018 – Kaleido Biosciences, a healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ, today announced the appointment of Katharine Knobil, M.D., as chief medical officer (CMO) and head of research

ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting

From Startup ARQULE Link to Full Article: -ARQ 531 demonstrates anti-tumor activity and favorable safety profile -Dose escalation to continue – Call with management scheduled for 12/3 at 9:00 ET to discuss the results BURLINGTON, Mass.–(BUSINESS WIRE)–Dec. 3, 2018– ArQule, Inc. (Nasdaq: ARQL) yesterday presented preliminary results from the Company’s

Mr. Y. Mark Xu, Chairman of Xynomic Pharma Presented at the BioCentury China Healthcare Summit 2018

From Startup Xynomic Pharma Link to Full Article: http://xynomicpharma.com/en/1980-3/ China’s Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China Healthcare Summit asked how the nation would

Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-positive-data-interim-analysis-exploratory-study Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects Observed corresponding trends of improvement on multiple secondary endpoints, including average daily pain scores and the Revised Fibromyalgia Impact Questionnaire (FIQR) Data support further development

Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

From Startup Magenta Therapeutics Link to Full Article: https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-presents-preclinical-data-targeted-non CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 2, 2018– Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented preclinical research on its targeted conditioning programs at